Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases.
- 1 January 1997
- journal article
- research article
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 15 (5) , 499-508
- https://doi.org/10.1023/a:1018418725453
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- Suramin-Induced Decrease in Prostate-Specific Antigen Expression With No Effect on Tumor Growth in the LNCaP Model of Human Prostate CancerJNCI Journal of the National Cancer Institute, 1996
- How Much Can We Rely on the Level of Prostate-Specific Antigen as an End Point for Evaluation of Clinical Trials? A Word of Caution!JNCI Journal of the National Cancer Institute, 1996
- Matrilysin: An epithelial matrix metalloproteinase with potentially novel functionsThe International Journal of Biochemistry & Cell Biology, 1996
- Effect of Matrix Metalloproteinase Inhibitor Batimastat on Breast Cancer Regrowth and Metastasis in Athymic MiceJNCI Journal of the National Cancer Institute, 1995
- Expression and in‐situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancerInternational Journal of Cancer, 1995
- Inhibition of Growth of Human Tumor Cells in Nude Mice by a Metalloproteinase InhibitorAnnals of the New York Academy of Sciences, 1994
- Inhibition of the metastatic spread and growth of B16‐BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitorInternational Journal of Cancer, 1994
- Prediction of Response to Drug Therapy of CancerDrugs, 1992
- The matrix‐degrading metalloproteinasesBioEssays, 1992
- A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomasNature, 1990